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We examined the need to improve our ability
to explain the unexplained in clinical infectious
diseases, primarily through improvements in
diagnostic technology. Part of the motivation for
this effort came from an Emerging Infectious
Disease Program (funded by the National Center
for Infectious Diseases, Centers for Disease
Control and Prevention [CDC]) to conduct
surveillance for unexplained deaths and critical
illnesses due to possibly infectious causes. This
project has found that the number of such
patients in the United States is substantial and
that a probable causative agent can be identified
in only a small fraction of these patients.
John Bartlett, Johns Hopkins University,
Baltimore, Maryland, and Sherif Zaki, CDC,
Atlanta, Georgia, addressed the current status
and offered their perspectives on pneumonia,
particularly acute respiratory distress syndrome
(ARDS) and hemorrhagic pneumonia, syndromes
frequently associated with unexplained critical
illness. Greg Kovacs, Stanford University, Stanford,
California, and Michael Eisen, Stanford University
School of Medicine, Stanford, California, presented
possible technologies and approaches to improving
diagnostic capabilities—a sensitive biologic detec-
tion system (for toxins and host gene expression
responses) for diagnosing infectious diseases.
Pneumonia—Evolving Diagnostic
Practices
Pneumonia, the most common infectious
cause of death in the United States, accounts for
approximately 45,000 deaths annually. In large
hospital-based studies, no causative agent can be
identified in 35% of community-acquired pneu-
monia cases. In actual practice, this proportion is
probably 50% to 75%.
Over the last three decades, the proportion of
community-acquired pneumonia cases in which
Streptococcus pneumoniae was isolated has
substantially declined. In the 1970s, the
proportion was 62%; in the 1980s, 40%; and in
1991, 18%. Why has the recovery of pneumococci
from patients with community-acquired pneumo-
nia changed so dramatically? Have the causes of
community-acquired pneumonia changed? Stan-
dard “gumshoe” microbiology to isolate pneumo-
cocci has taken a devastating hit in the 1990s due
to outsourcing of microbiology services or just
decreased emphasis on standard microbiology
practices (e.g., collection and handling of clinical
specimens). Newly recognized agents such as
Legionella pneumophila may also explain some
of the decrease in the proportion of pneumo-
cocci isolated.
Recommendations for the evaluation and
management of community-acquired pneumo-
nia, developed by the Infectious Disease Society
of America, were published in the April issue of
Clinical Infectious Diseases. These recommenda-
tions detail diagnostic tests as well as inadequa-
cies in diagnostic technologies for several of the
common causes of community-acquired pneumo-
nia, including Chlamydia pneumoniae, L.
pneumophila, and Mycoplasma pneumoniae.
Pathologic Approach to the Diagnosis of
Infectious Causes of Pulmonary
Hemorrhage and Acute Respiratory
Distress Syndrome
Pathologists should recognize patterns of
tissue injury (especially in the lung parenchyma)
that react in specific and predictable ways. This
approach narrows diagnostic options and focuses
testing efforts. Acute lung injury (e.g., diffuse
alveolar damage or ARDS) and air space filling
patterns (e.g., hemorrhage and pulmonary
edema) of lung injury are two important patterns
manifesting infectious disease. Examples include
diffuse alveolar damage associated with adenovi-
rus infection (smudge cells may be seen); measles
(giant cells); respiratory syncytial virus (RSV)
infection; influenza infections; Rocky Mountain
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spotted fever; typhus; legionnella; mycoplasma;
and hemorrhage associated with aspergillosis,
mucormycosis, leptospirosis, dengue, yellow
fever, Lassa, and Ebola virus infection. The
recognition of these patterns (combined with
application of special stains, immunohistochemi-
cal reagents, and in situ hybridization) is a
powerful tool in the diagnosis of unexplained
critical infectious diseases.
Two examples of the application of these
combined methods to the identification of
infectious agents are the 1993 hantavirus
epidemic in the southwestern United States and
the 1995 leptospirosis epidemic in Nicaragua. In
the hantavirus epidemic, healthy young adults
contracted fever and rapidly progressive pulmo-
nary disease consistent with ARDS, and many
died within days of the onset of illness. Testing for
a wide variety of agents was negative. Lung
tissue showed interstitial pneumonitis and
interalveolar edema; these patterns were consis-
tent with viral pneumonia or toxic change. After
serum samples from these patients were found to
cross-react with known hantaviruses, antibodies
were used to demonstrate hantavirus in the lung,
kidney, and muscle tissues. In the leptospirosis
epidemic, after heavy rains in northern Nicara-
gua, a number of persons became ill with fever,
headache, muscle aches, hemorrhage, and severe
ARDS; no prominent renal or hepatic manifesta-
tions were observed. Initial testing focused on
hantavirus, dengue, and other viral agents, but
results were negative. Pathologic examination of
tissue from fatal cases showed pulmonary
hemorrhage and diffuse alveolar damage, as well
as renal and hepatic changes. In the 1980s,
reports of leptospirosis epidemics in Korea and
China prompted investigators to develop an
immunohistochemical test for leptospirosis; the
disease was subsequently found in kidney, liver,
and lung specimens of Nicaraguan patients.
Novel Bioassay for Detecting Toxin-Mediated
Illness
 The impetus for this project has been
twofold: military detection of chemical and
biological warfare agents and pharmaceutical
screening. Cells are cultured on silicon chips, and
their response to toxins is monitored in several
ways (e.g., action potential for electrically active
cells, impedance, and motility). These systems
complement other approaches because they allow
detection of unknown or unrecognized toxins. A
cell monolayer is incredibly responsive because of
its diffusion characteristics; this responsiveness
can be tuned by selection of cells and through
engineering. The use of cocultures can allow
diversity in detection and response characteris-
tics. In addition to detecting chemical and
biological warfare agents, these systems can
screen for antidotes by challenging the system
with the toxin and adding a putative antidote.
Pharmaceutical companies are interested in
using this system for early screening of drug
actions on cell physiology.
Chick myocardial cells and NG108 neuro-
blastoma hybrid cell lines were used to examine
the shape and frequency of action potentials.
Exposure of these cells to agents with known
effects on cell physiology (e.g., epinephrine,
verapamil, and tetrodotoxin) causes predictable
changes (depending on the interaction of these
toxins with transmembrane channels) on the
shape of action potential curves when deviation
from baseline is used as the internal control on
response. Impedance measurement (alteration in
electrical current after passage through a cell)
can also be used to reflect changes in the cell
membrane as a result of exposure to a toxin. The
effect of toxins on the cytoskeleton can also be
measured by cell motility through impedance.
When this technology was first developed, it
required approximately 1 m3 of electronics support,
but with silicon chips a laptop computer can now
support the operation. A Windows application can
handle the data processing, and the technology can
be transferred to other laboratories.
Cellular Scouts: Genome-Wide Expression
Monitoring of Peripheral Blood to Detect and
Characterize Pathogens
Using an easily constructed robot, we have
been building DNA microarrays in which each
dot represents different open reading frames. In
the fully sequenced genome of Saccharomyces
cerevisiae, there are 6,200 dots or open reading
frames. The Human Genome Project has
identified approximately 50,000 distinct cDNA
sequences, and we have been using microarrays
with approximately 15,000 of these. By the end of
1998, we will have all 50,000 genes on a
microarray. For these assays we use a control and
an experimental sample. From these samples, we
isolate polyadentylated RNA by using any of a
variety of kits, and then make fluorescently
labeled cDNA copies, with each of the two397 Vol. 4, No. 3, July–September 1998 Emerging Infectious Diseases
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samples labeled with a different color (e.g., one
green and the other red). RNA is degraded to
avoid any confounding signals; the samples are
mixed and then hybridized to the microarray. The
microarray is imaged by using a scanning laser
confocal microscope, and through a process of
quantitation, the relative representation of every
gene in sample 1 versus sample 2 is calculated.
These data provide a very high resolution
fingerprint of what is going on in any cell(s) of
interest. So when a sample from a healthy person is
compared with one from an ill person, differences in
gene expression should be sufficiently unique to
diagnose particular infections.
First, however, we would like to know that
cells respond to internal and external stimuli by
at least some differences in expression of their
genes, that specific stimuli result in distinct gene
expression patterns, and that the response to
stimuli evolves in a stereotypic temporal manner.
Ideally, we would like not only to diagnose a
particular infection but also to determine the
stage of that infection. Preliminary data from our
laboratory support these hypotheses. The
patterns of human gene response to different
stimuli, including T-cells stimulated with
mitogens, cells exposed to DNA damaging agents,
and cells infected with polio and cytomegalovirus
have distinct DNA expression patterns, or “bar
codes,” that change over time. Although we have
not processed a wide selection of infectious agents,
we have evaluated approximately 60 distinct
human tumor cell lines using a common control cell
line. When we used these data for phylogenetic
reconstruction, we found very good clustering with
respect to the tissue of origin. Specific signatures
are related to central nervous system tumors,
kidney tumors, melanomas, and leukemias.
We would like to focus on the use of peripheral
blood cells as a sort of infectious disease sensor.
There are a number of reasons to believe that this
may work. We have data from human lymphocytes
harvested from whole blood (where one sample is
exposed to interleukin-2 and the other is not) and
we can demonstrate many changes in gene
expression. To make this approach useful, we will
need a broad range of gene array data from
persons with known causes of illness.